Ukraine Parliament Votes to Legalize Medical Marijuana

Regulations by 2FIRSTS.ai

Dec.22.2023

Ukraine Parliament Votes to Legalize Medical Marijuana

Ukraine's Parliament votes to legalize medical marijuana following war-related PTSD cases, with strict control on production and sales.

On December 21st, the Ukrainian Parliament voted in favor of legalizing medical cannabis, following a war with Russia that has resulted in thousands of people suffering from post-traumatic stress disorder. Many believe that this condition can be alleviated through medication, according to a report by the Associated Press.

The new law will come into effect six months from now, allowing for the scientific and industrial use of marijuana. It was passed in the Kiev Parliament with 248 votes out of the 401 seats. Details of the voting were not provided at the time. The law was proposed by Prime Minister Denys Smyhal.

The possibility of legalizing medical cannabis has been a long-standing debate in Ukraine. Many people endorse the benefits of cannabis for medical treatment, while others express concerns that legalizing medical marijuana may result in an influx of drugs into Ukrainian urban streets.

The measure imposes strict control over the production and sale of marijuana. Any medication containing cannabis derivatives requires a prescription from a doctor. The recreational use of marijuana remains classified as a criminal offense.

References:

[1] Ucrania aprueba legalizar marihuana medicinal, luego de que guerra causara estrés a miles Agencias

Also Read:

[1] Controversy Surrounding the Legalization of Marijuana in Colombia

[2] Controversial Revisions Proposed for Ohio's Marijuana Legalization Initiative

[3] Ohio Voters Approve Proposal to Legalize Recreational Marijuana

[4] Health Problems on the Rise Since Cannabis Legalization

#Europe #Legislation #UK #CBD #Ukraine #The United Kingdom #Marijuana #European Parliament #Medical marijuana dispensary

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

Copyright

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

CSUR, the Research Institute Supporting Juul’s PMTA Research, Outlines a New Pathway for Nicotine Pouches

CSUR—the Research Institute Supporting Juul and NJOY’s successful PMTAs—assessed FDA’s pilot for nicotine pouches. The program expedites premarket review by deferring behavioral data to post-market reporting. CSUR says this could speed authorizations, but manufacturers must still produce behavioral and real-world evidence after a Marketing Granted Order to maintain compliance with public-health standards.

Nov.04

UK Experts Raise Concerns Over High-Dose Nicotine Pouches Amid Rising Sales

According to The Guardian, health experts in the UK are warning about the potential health effects of high-dose nicotine pouches as their sales continue to rise. Recent studies show teenagers reporting nicotine rushes, sickness and fainting, while researchers say packaging and marketing increasingly appeal to younger age groups. Although viewed as less harmful than cigarettes, experts remain concerned about their use among non-smokers, especially adolescents.

Nov.13 by 2FIRSTS.ai

Product | INNOKIN Launches Magnetic Open-System Device, Pod + Power Bank Design Debuts in UK and US Channels

INNOKIN has recently launched its new open-system e-cigarette, EZ LEVA, on its official website, and it is now available through online channels in the UK and the United States. Featuring a magnetic design, the device adopts a pod + power bank form factor. Its 400mAh (device) + 2000mAh (charging case) battery setup follows a similar configuration logic to comparable products such as the SMOK Airmate and KIWI 2.

Dec.09 by 2FIRSTS.ai

Wales Passes Law Banning Tobacco Sales to Anyone Born After 2009

The Welsh Parliament (Senedd) has approved new legislation banning tobacco sales to anyone born on or after January 1, 2009. The law, passed on December 9, 2025, also imposes stricter controls on how vapes and nicotine products are advertised and sold. Designed by the UK Government but voted on separately in Wales, the bill passed with 36 votes in favor, two abstentions, and nine against. It grants stronger enforcement powers to Trading Standards to combat illegal tobacco and vape sales.